Regulus Therapeutics Stock Price, News & Analysis (NASDAQ:RGLS)

$1.21 -0.02 (-1.63 %)
(As of 02/22/2018 02:06 PM ET)
Previous Close$1.21
Today's Range$1.20 - $1.24
52-Week Range$0.79 - $1.95
Volume154,700 shs
Average Volume544,192 shs
Market Capitalization$124.75 million
P/E Ratio-0.91
Dividend YieldN/A
Beta1.72

About Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics logoRegulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Receive RGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:RGLS
CUSIP75915K10
Phone+1-858-2026300

Debt

Debt-to-Equity Ratio0.41%
Current Ratio6.77%
Quick Ratio6.77%

Price-To-Earnings

Trailing P/E Ratio-0.91044776119403
Forward P/E Ratio-1.17
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.19 million
Price / Sales105.71
Cash FlowN/A
Price / CashN/A
Book Value$1.06 per share
Price / Book1.14

Profitability

Trailing EPS($1.34)
Net Income$-81,830,000.00
Net Margins-107,606.96%
Return on Equity-189.71%
Return on Assets-92.92%

Miscellaneous

Employees97
Outstanding Shares103,960,000

Regulus Therapeutics (NASDAQ:RGLS) Frequently Asked Questions

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc (NASDAQ:RGLS) released its quarterly earnings results on Tuesday, August, 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.02. The biopharmaceutical company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.50 million. Regulus Therapeutics had a negative return on equity of 189.71% and a negative net margin of 107,606.96%. View Regulus Therapeutics' Earnings History.

When will Regulus Therapeutics make its next earnings announcement?

Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for Regulus Therapeutics.

Where is Regulus Therapeutics' stock going? Where will Regulus Therapeutics' stock price be in 2018?

7 analysts have issued 12-month price objectives for Regulus Therapeutics' stock. Their predictions range from $1.00 to $4.00. On average, they anticipate Regulus Therapeutics' share price to reach $2.70 in the next year. View Analyst Ratings for Regulus Therapeutics.

What are Wall Street analysts saying about Regulus Therapeutics stock?

Here are some recent quotes from research analysts about Regulus Therapeutics stock:

  • 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (1/25/2018)
  • 2. Needham & Company LLC analysts commented, "Regulus reported 3Q17 financial results last wk and we met w/ mgmt for an update today. Both planned clinical trials of RG-012 in Alport Syndrome pts are now underway and an IND has been submitted for RGLS4326 in Autosomal Dominant Polycystic Kidney Disease. Mgmt has identified male X-linked Alport Syndrome as target pt population for clinical development going forward, due to rapid and homogeneous disease progression. We expect top-line results from 10- patient RG-012 biopsy trial early next yr and from 40-patient RG-012 HERA Phase 2 efficacy trial in early 2019. Maintain HOLD, awaiting more data from lead RG-012 program, but also note encouraging progression of platform/ pipeline behind it." (11/14/2017)

Who are some of Regulus Therapeutics' key competitors?

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Chairman of the Board (Age 68)
  • Joseph P. Hagan, President, Chief Executive Officer, Principal Executive Officer, Director (Age 48)
  • Daniel Chevallard, Chief Financial Officer, Principal Financial and Accounting Officer
  • Mark Deeg, Chief Medical Officer
  • B. Lynne Parshall J.D., Director (Age 63)
  • Douglas E. Williams Ph.D., Director (Age 59)
  • David Baltimore Ph.D., Independent Director (Age 79)
  • Mark G. Foletta CPA, Independent Director (Age 55)
  • William H. Rastetter Ph.D., Independent Director (Age 68)

Who owns Regulus Therapeutics stock?

Regulus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BVF Inc. IL (13.44%), Broadfin Capital LLC (1.45%), Ascend Capital LLC (0.98%), Candriam Luxembourg S.C.A. (0.48%), Wells Fargo & Company MN (0.38%) and Victory Capital Management Inc. (0.32%). Company insiders that own Regulus Therapeutics stock include Alnylam Pharmaceuticals, Inc, Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.

Who sold Regulus Therapeutics stock? Who is selling Regulus Therapeutics stock?

Regulus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Wells Fargo & Company MN and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Regulus Therapeutics.

Who bought Regulus Therapeutics stock? Who is buying Regulus Therapeutics stock?

Regulus Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Ascend Capital LLC, Renaissance Technologies LLC and Victory Capital Management Inc.. Company insiders that have bought Regulus Therapeutics stock in the last two years include Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Insider Buying and Selling for Regulus Therapeutics.

How do I buy Regulus Therapeutics stock?

Shares of Regulus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regulus Therapeutics' stock price today?

One share of Regulus Therapeutics stock can currently be purchased for approximately $1.21.

How big of a company is Regulus Therapeutics?

Regulus Therapeutics has a market capitalization of $124.75 million and generates $1.19 million in revenue each year. The biopharmaceutical company earns $-81,830,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. Regulus Therapeutics employs 97 workers across the globe.

How can I contact Regulus Therapeutics?

Regulus Therapeutics' mailing address is 10614 Science Center Dr, SAN DIEGO, CA 92121-1150, United States. The biopharmaceutical company can be reached via phone at +1-858-2026300 or via email at [email protected]


MarketBeat Community Rating for Regulus Therapeutics (RGLS)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  477
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Regulus Therapeutics (NASDAQ:RGLS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.432.382.292.29
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.70$2.70$2.88$4.10
Price Target Upside: 92.86% upside92.86% upside215.93% upside340.39% upside

Regulus Therapeutics (NASDAQ:RGLS) Consensus Price Target History

Price Target History for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Chardan CapitalReiterated RatingNeutralLowView Rating Details
1/5/2018Leerink SwannInitiated CoverageOutperform -> Outperform$2.00HighView Rating Details
12/11/2017WedbushReiterated RatingOutperform$4.00HighView Rating Details
11/14/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
6/12/2017BMO Capital MarketsSet Price TargetHold$1.00LowView Rating Details
3/3/2017CowenReiterated RatingHoldN/AView Rating Details
3/3/2017Cantor FitzgeraldLower Price TargetBuy$7.00 -> $4.00N/AView Rating Details
1/30/2017Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
6/28/2016FBR & CoReiterated RatingOutperform$30.00 -> $9.00N/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Regulus Therapeutics (NASDAQ:RGLS) Earnings History and Estimates Chart

Earnings by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ RGLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2018($0.15)N/AView Earnings Details
11/7/2017Q3 2017($0.18)($0.18)$0.02 million$0.02 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.31)($0.41)$0.02 million$0.02 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.33)($0.38)$0.02 million$0.02 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.37)($0.38)$0.20 million$0.02 millionViewListenView Earnings Details
11/1/2016Q3 2016($0.39)($0.37)$0.50 million$0.20 millionViewN/AView Earnings Details
8/2/2016Q216($0.38)($0.40)$0.50 million$0.48 millionViewListenView Earnings Details
5/2/2016Q1($0.33)($0.40)$2.25 million$0.49 millionViewListenView Earnings Details
2/22/2016Q415($0.25)($0.14)$5.09 million$10.90 millionViewListenView Earnings Details
11/5/2015Q315($0.37)($0.25)$3.57 million$1.87 millionViewN/AView Earnings Details
8/4/2015Q215($0.29)($0.41)$2.40 million$3.80 millionViewN/AView Earnings Details
5/7/2015($0.26)($0.25)$3.38 million$4.20 millionViewListenView Earnings Details
2/18/2015($0.21)($0.47)$2.24 million$4.22 millionViewListenView Earnings Details
11/5/2014($0.23)($0.23)$2.76 million$1.08 millionViewListenView Earnings Details
8/6/2014Q214($0.19)($0.29)$3.20 million$0.74 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.30)$3.80 million$1.63 millionViewN/AView Earnings Details
2/27/2014($0.13)($0.11)$3.69 million$5.45 millionViewN/AView Earnings Details
11/13/2013Q3 2013($0.16)($0.07)$3.56 million$6.12 millionViewN/AView Earnings Details
8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView Earnings Details
5/14/2013Q1 2013($0.09)($0.20)$2.96 million$3.24 millionViewN/AView Earnings Details
2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView Earnings Details
11/19/2012Q312($15.98)$3.81 million$2.80 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Regulus Therapeutics (NASDAQ:RGLS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.45)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.12)($0.12)($0.12)
Q2 20181($0.11)($0.11)($0.11)
Q3 20181($0.11)($0.11)($0.11)
Q4 20181($0.11)($0.11)($0.11)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Regulus Therapeutics (NASDAQ:RGLS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Regulus Therapeutics (NASDAQ RGLS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 57.83%
Insider Trades by Quarter for Regulus Therapeutics (NASDAQ:RGLS)
Institutional Ownership by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ RGLS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/25/2017Daniel R ChevallardCFOBuy54,945$0.91$49,999.9559,415View SEC Filing  
7/25/2017Joseph P HaganInsiderBuy219,780$0.91$199,999.80241,297View SEC Filing  
7/25/2017William H RastetterDirectorBuy274,725$0.91$249,999.75View SEC Filing  
3/22/2017Stelios PapadopoulosDirectorBuy500,000$1.22$610,000.00400,677View SEC Filing  
3/7/2017William H RastetterDirectorBuy250,000$1.15$287,500.00View SEC Filing  
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.0010,000View SEC Filing  
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.004,896,716View SEC Filing  
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00View SEC Filing  
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45View SEC Filing  
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80View SEC Filing  
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00View SEC Filing  
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00View SEC Filing  
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80View SEC Filing  
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00View SEC Filing  
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00View SEC Filing  
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00View SEC Filing  
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00View SEC Filing  
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34View SEC Filing  
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68View SEC Filing  
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00View SEC Filing  
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00View SEC Filing  
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00View SEC Filing  
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00View SEC Filing  
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00View SEC Filing  
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00View SEC Filing  
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00View SEC Filing  
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00View SEC Filing  
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50View SEC Filing  
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00View SEC Filing  
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00View SEC Filing  
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50View SEC Filing  
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00View SEC Filing  
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50View SEC Filing  
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00View SEC Filing  
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00View SEC Filing  
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00View SEC Filing  
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00View SEC Filing  
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00View SEC Filing  
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00View SEC Filing  
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00View SEC Filing  
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00View SEC Filing  
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00View SEC Filing  
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50View SEC Filing  
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00View SEC Filing  
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00View SEC Filing  
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30View SEC Filing  
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00View SEC Filing  
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50View SEC Filing  
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00View SEC Filing  
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00View SEC Filing  
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00View SEC Filing  
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00View SEC Filing  
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00View SEC Filing  
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00View SEC Filing  
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00View SEC Filing  
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00View SEC Filing  
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00View SEC Filing  
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00View SEC Filing  
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00View SEC Filing  
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00View SEC Filing  
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50View SEC Filing  
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00View SEC Filing  
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00View SEC Filing  
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00View SEC Filing  
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00View SEC Filing  
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00View SEC Filing  
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00View SEC Filing  
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00View SEC Filing  
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View SEC Filing  
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.8950,000View SEC Filing  
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.8550,000View SEC Filing  
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.0050,000View SEC Filing  
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View SEC Filing  
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Regulus Therapeutics (NASDAQ RGLS) News Headlines

Source:
DateHeadline
WuXi STA and Regulus Announce microRNA Development and Manufacturing CollaborationWuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration
finance.yahoo.com - February 22 at 8:24 AM
Regulus Therapeutics (RGLS) Set to Announce Quarterly Earnings on WednesdayRegulus Therapeutics (RGLS) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 21 at 2:40 AM
This Mornings Technical Outlook on Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health, and ... - PR Newswire (press release)This Morning's Technical Outlook on Biotech Stocks -- Portola Pharma, Protalix BioTherapeutics, Radius Health, and ... - PR Newswire (press release)
www.prnewswire.com - February 13 at 7:19 AM
Regulus Therapeutics Inc Forecasted to Post FY2022 Earnings of $0.47 Per Share (RGLS)Regulus Therapeutics Inc Forecasted to Post FY2022 Earnings of $0.47 Per Share (RGLS)
www.americanbankingnews.com - February 12 at 9:52 AM
Regulus to Participate in the LEERINK Partners 7th Annual Global ... - PR Newswire (press release)Regulus to Participate in the LEERINK Partners 7th Annual Global ... - PR Newswire (press release)
www.prnewswire.com - February 9 at 7:16 AM
Regulus to Participate in the LEERINK Partners 7th Annual Global Healthcare ConferenceRegulus to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 9 at 7:16 AM
Regulus Therapeutics Inc (RGLS) Receives Consensus Rating of "Hold" from AnalystsRegulus Therapeutics Inc (RGLS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 30 at 9:39 AM
Regulus Therapeutics (RGLS) Downgraded by Zacks Investment ResearchRegulus Therapeutics (RGLS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 25 at 11:48 PM
Zacks Investment Research Upgrades Regulus Therapeutics (RGLS) to BuyZacks Investment Research Upgrades Regulus Therapeutics (RGLS) to Buy
www.americanbankingnews.com - January 24 at 11:46 AM
Regulus Therapeutics (RGLS) Earns "Neutral" Rating from Chardan CapitalRegulus Therapeutics (RGLS) Earns "Neutral" Rating from Chardan Capital
www.americanbankingnews.com - January 20 at 6:28 AM
Regulus Therapeutics (RGLS) Rating Lowered to Hold at Zacks Investment ResearchRegulus Therapeutics (RGLS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 18 at 1:50 PM
UPDATE: Leerink Partners Starts Regulus Therapeutics (RGLS) at Outperform - StreetInsider.comUPDATE: Leerink Partners Starts Regulus Therapeutics (RGLS) at Outperform - StreetInsider.com
www.streetinsider.com - January 5 at 10:02 AM
Regulus Therapeutics Inc (RGLS) Given Average Rating of "Hold" by AnalystsRegulus Therapeutics Inc (RGLS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 5 at 10:00 AM
Regulus Therapeutics (RGLS) Now Covered by Leerink SwannRegulus Therapeutics (RGLS) Now Covered by Leerink Swann
www.americanbankingnews.com - January 5 at 8:54 AM
Regulus Therapeutics (RGLS) Upgraded at Zacks Investment ResearchRegulus Therapeutics (RGLS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 4 at 8:08 PM
Technical Perspectives on Argos Therapeutics, Omeros, Regulus Therapeutics, and Rhythm PharmaTechnical Perspectives on Argos Therapeutics, Omeros, Regulus Therapeutics, and Rhythm Pharma
www.prnewswire.com - December 26 at 7:37 AM
Wave Life Sciences (WVE) & Regulus Therapeutics (RGLS) Financial ComparisonWave Life Sciences (WVE) & Regulus Therapeutics (RGLS) Financial Comparison
www.americanbankingnews.com - December 22 at 1:24 PM
Regulus Therapeutics (RGLS) Announces First-in-Human Dosing for Phase I Study of RGLS4326 for Treatment of ... - StreetInsider.comRegulus Therapeutics (RGLS) Announces First-in-Human Dosing for Phase I Study of RGLS4326 for Treatment of ... - StreetInsider.com
www.streetinsider.com - December 20 at 3:28 PM
BRIEF-Regulus Announces First-in-Human Dosing For Phase I Study Of RGLS4326BRIEF-Regulus Announces First-in-Human Dosing For Phase I Study Of RGLS4326
www.reuters.com - December 19 at 9:53 AM
Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney DiseaseRegulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease
finance.yahoo.com - December 19 at 9:53 AM
Wedbush Comments on Regulus Therapeutics Incs FY2017 Earnings (RGLS)Wedbush Comments on Regulus Therapeutics Inc's FY2017 Earnings (RGLS)
www.americanbankingnews.com - December 13 at 8:08 AM
Regulus Therapeutics Inc. (RGLS) Receives Consensus Rating of "Hold" from AnalystsRegulus Therapeutics Inc. (RGLS) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - December 11 at 11:42 AM
Regulus Therapeutics (RGLS) Stock Rating Reaffirmed by WedbushRegulus Therapeutics (RGLS) Stock Rating Reaffirmed by Wedbush
www.americanbankingnews.com - December 11 at 9:00 AM
Analyzing Abeona Therapeutics (ABEO) & Regulus Therapeutics (RGLS)Analyzing Abeona Therapeutics (ABEO) & Regulus Therapeutics (RGLS)
www.americanbankingnews.com - December 10 at 3:54 PM
Regulus Therapeutics Inc. (RGLS) Short Interest UpdateRegulus Therapeutics Inc. (RGLS) Short Interest Update
www.americanbankingnews.com - November 30 at 6:22 AM
Reviewing Regulus Therapeutics (RGLS) and Its PeersReviewing Regulus Therapeutics (RGLS) and Its Peers
www.americanbankingnews.com - November 29 at 3:20 PM
Regulus Therapeutics Inc. (RGLS) Earns Hold Rating from Needham & Company LLCRegulus Therapeutics Inc. (RGLS) Earns Hold Rating from Needham & Company LLC
www.americanbankingnews.com - November 14 at 10:26 PM
Regulus Therapeutics Inc. to Host Earnings CallRegulus Therapeutics Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 12:26 PM
Regulus Reports Third Quarter 2017 Financial Results and Recent EventsRegulus Reports Third Quarter 2017 Financial Results and Recent Events
finance.yahoo.com - November 9 at 12:26 PM
Regulus reports 3Q lossRegulus reports 3Q loss
finance.yahoo.com - November 9 at 12:26 PM
Edited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMTEdited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMT
finance.yahoo.com - November 9 at 12:26 PM
Regulus Therapeutics Inc. (RGLS) Issues Quarterly  Earnings ResultsRegulus Therapeutics Inc. (RGLS) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 7 at 6:35 PM
Regulus Therapeutics Inc. (RGLS) Set to Announce Earnings on TuesdayRegulus Therapeutics Inc. (RGLS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - November 1 at 10:49 AM
Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017
finance.yahoo.com - November 1 at 8:09 AM
Head-To-Head Survey: Regulus Therapeutics (RGLS) vs. The CompetitionHead-To-Head Survey: Regulus Therapeutics (RGLS) vs. The Competition
www.americanbankingnews.com - November 1 at 1:20 AM
Regulus Therapeutics Inc. (RGLS) to Release Earnings on MondayRegulus Therapeutics Inc. (RGLS) to Release Earnings on Monday
www.americanbankingnews.com - October 23 at 9:40 AM
Regulus Therapeutics Inc. (RGLS) Receives Average Recommendation of "Hold" from AnalystsRegulus Therapeutics Inc. (RGLS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 22 at 11:02 AM
Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in SessionRegulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session
finance.yahoo.com - October 3 at 11:41 AM
Head-To-Head Contrast: Regulus Therapeutics (RGLS) and Codexis (CDXS)Head-To-Head Contrast: Regulus Therapeutics (RGLS) and Codexis (CDXS)
www.americanbankingnews.com - September 30 at 6:15 PM
Regulus Therapeutics Inc. (RGLS) Given Consensus Recommendation of "Hold" by AnalystsRegulus Therapeutics Inc. (RGLS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 27 at 10:36 AM
Regulus Therapeutics Inc. (RGLS) Sees Significant Increase in Short InterestRegulus Therapeutics Inc. (RGLS) Sees Significant Increase in Short Interest
www.americanbankingnews.com - September 16 at 1:20 AM
Regulus to Present at the 2017 Wells Fargo Healthcare ConferenceRegulus to Present at the 2017 Wells Fargo Healthcare Conference
finance.yahoo.com - August 31 at 9:25 AM
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? - NasdaqAre Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? - Nasdaq
www.nasdaq.com - August 26 at 8:50 AM
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?
finance.yahoo.com - August 25 at 10:53 AM
Brokers Issue Forecasts for Regulus Therapeutics Inc.s Q3 2017 Earnings (NASDAQ:RGLS)Brokers Issue Forecasts for Regulus Therapeutics Inc.'s Q3 2017 Earnings (NASDAQ:RGLS)
www.americanbankingnews.com - August 9 at 7:28 AM
Regulus to Present at the 2017 Wedbush PacGrow Healthcare ConferenceRegulus to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 6:56 AM
Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of "Hold" by BrokeragesRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 8 at 11:04 AM
Regulus Therapeutics Inc. (RGLS) Earns "Ourperform" Rating from WedbushRegulus Therapeutics Inc. (RGLS) Earns "Ourperform" Rating from Wedbush
www.americanbankingnews.com - August 7 at 11:20 AM
Regulus Therapeutics (RGLS) Hold Rating Reaffirmed at Needham & Company LLCRegulus Therapeutics' (RGLS) Hold Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - August 2 at 4:38 PM
Regulus Therapeutics Inc. (RGLS) Releases Quarterly  Earnings Results, Misses Estimates By $0.10 EPSRegulus Therapeutics Inc. (RGLS) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - August 2 at 12:40 PM

SEC Filings

Regulus Therapeutics (NASDAQ:RGLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Regulus Therapeutics (NASDAQ:RGLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Regulus Therapeutics (NASDAQ RGLS) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.